New Drug for Soft Tissue Sarcoma Doing Well in Clinical Trials
The abstract, "Aldoxorubicin (INNO-206) is an active drug for the treatment of relapsed or refractory soft tissue sarcomas," will be presented by the clinical trial's principal investigator Dr. Sant Chawla, M.D., F.R.A.C.P. Dr. Chawla, a world renowned expert in the treatment of soft tissue sarcomas, is Director of the Sarcoma Oncology Center in Santa Monica, Calif. The Phase 1b/2 clinical trial results, first announced in early June 2012 at the American Society of Clinical Oncology (ASCO) conference, showed clinical benefit (defined as partial response and stable disease of more than four months following up to eight cycles of treatment) with aldoxorubicin at the maximum tolerated dose in 10 of 13 evaluable patients with advanced, metastatic soft tissue sarcomas who had either not responded or relapsed after receiving one to three prior chemotherapies. Eight of the 13 patients had been treated previously with doxorubicin.